Percubaan Terkawal Rawak Global SPARX oleh Translumina Dimulakan untuk Memajukan Bukti untuk Belon Bersalut Ubat dalam Penyakit Koronari Kompleks

Trial StartDrug-coated balloon (DCB)Neutral

AI Analysis

Summary

Translumina has officially launched the global SPARX randomized controlled trial, a multinational study evaluating a drug-coated balloon (DCB)-first strategy against drug-eluting stents in complex coronary artery disease. The announcement was dated October 13, 2026 from Lucerne, Switzerland and New Delhi.

Clinical Trial Data

Outcome Details

SPARX Global RCT officially initiated to evaluate a DCB-first strategy versus drug-eluting stents in complex coronary disease

Importance:3/10

Sentiment:

0.20

trial startdrug-coated ballooncoronary artery diseasemedical devicerandomized controlled trialcardiologyinterventional cardiology

Related Companies

$GBCMD

Read the original article

Published by PR Newswire Pharma on October 12, 2026 10:28 PM

Read Original